Geniposide decreases the level of Aβ1-42 in the hippocampus of streptozotocin-induced diabetic rats

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 9, 2013, Pages 787-791

  Liu, Jianhui ^a,b   Zhang, Yonglan ^a,b   Deng, Xiaohong ^a,b   Yin, Fei ^a,b  

^a CHONGQING TECHNOLOGY AND BUSINESS UNIVERSITY   (China)

^b CHONGQING UNIVERSITY   (China)

Author keywords

amyloid (a ); Alzheimer's disease (ad); Diabetes; Geniposide; Insulin degrading enzyme (ide)

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); CHOLESTEROL; GENIPOSIDE; INSULIN; INSULINASE; IRIDOID; PEPTIDE FRAGMENT; TRIACYLGLYCEROL;

ALZHEIMER'S DISEASE (AD); ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GARDENIA; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; HUMAN; INSULIN-DEGRADING ENZYME (IDE); MALE; METABOLISM; PHYTOTHERAPY; RAT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; WESTERN BLOTTING; Β-AMYLOID (AΒ);

ALZHEIMER'S DISEASE (AD); DIABETES; GENIPOSIDE; INSULIN-DEGRADING ENZYME (IDE); Β-AMYLOID (AΒ);

AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; CELL LINE, TUMOR; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GARDENIA; HIPPOCAMPUS; HUMANS; INSULIN; INSULYSIN; IRIDOIDS; MALE; PEPTIDE FRAGMENTS; PHYTOTHERAPY; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 84883244791     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt069     Document Type: Article

References (20)

1. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA and Seshadri S. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 2006, 63: 1551-1555.
2. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA and Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004, 61: 661-666.
3. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A and Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53: 1937-1942.
4. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev 2009, 4: 373-379.
5. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B and Sulkava R, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010, 75: 1195-1202.
6. Sims-Robinson C, Kim B, Rosko A and Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 2010, 6: 551-559.
7. Kodl CT and Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008, 29: 494-511.
8. Craft S and Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004, 3: 169-178.
9. Gasparini L, Netzer WJ, Greengard P and Xu H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 2002, 23: 288-293.
10. Liu J, Yin F, Zheng X, Jing J and Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int 2007, 51: 361-369.
11. Liu J, Zheng X, Yin F, Hu Y, Guo L, Deng X and Chen G, et al. Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells. Int J Dev Neurosci 2006, 24: 419-424.
12. Liu JH, Yin F, Guo LX, Deng XH and Hu YH. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: Involvement of PI3 kinase signal pathway. Acta Pharmacol Sin 2009, 30: 159-165.
13. Yin F, Zhang Y, Guo L, Kong S and Liu J. Geniposide regulates insulindegrading enzyme expression to inhibit the cytotoxicity of Abeta1-42 in cortical neurons. CNS Neurol Disord Drug Targets 2012, 11: 1045-1051.
14. Reitz C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012, 2012: 369808.
15. Hardy JA and Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256: 184-185.
16. Cole AR, Astell A, Green C and Sutherland C. Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 2007, 31: 1046-1063.
17. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP and Eckman CB, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003, 100: 4162-4167.
18. Fernandez-Gamba A, Leal MC, Morelli L and Castano EM. Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease. Curr Pharm Des 2009, 15: 3644-3655.
19. Cook SE, Miyahara S, Bacanu SA, Perez-Madrinan G, Lopez OL, Kaufer DI and Nimgaonkar VL, et al. Psychotic symptoms in Alzheimer disease: evidence for subtypes. Am J Geriatr Psychiatry 2003, 11: 406-413.
20. Perez M, Rojo AI, Wandosell F, Diaz-Nido J and Avila J. Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J 2003, 372: 129-136.